SERO AS

SERO AS is listed at Stasjonsveien 44, 1396 Billingstad, Norway; website: https://sero.no/. Its company profile describes SERO as a European specialist in high-quality control sera. Listed industry: Health and life science.

Related solution: “SERO: pioneering trust in medical laboratory diagnostics” — https://businessnorway.com/solutions/sero-pioneering-trust-in-medical-laboratory-diagnostics. Published 22 Aug 2024; updated 23 Mar 2026. SERO supplies independent third-party quality-control materials used to check the accuracy and comparability of medical laboratory tests. Its history goes back to the 1950s, when Professor Lorentz Eldjarn at Oslo University Hospital developed control sera; SERO was established 13 years later and launched Seronorm®, described as the first commercially available control serum. The page notes Seronorm® Immunoassay Control contains over 50 analytes in one bottle. SERO’s independence from instrument manufacturers is presented as an alignment with laboratory quality standards. Most products are described as containing more than 95% human serum, without added stabilisers or preservatives, to make controls more patient-like and representative of real samples. The company also aims for universal controls compatible with different analytical platforms. The profile says it exports 90% of production, has partners on all continents and can register products globally through local partners. Listed availability: Americas, Europe, Asia, Africa and Oceania. Listed SDG: Good health and well-being.

Related articles: “Norway to bring a treasure trove of lifesaving medtech to global markets” — https://businessnorway.com/articles/norway-to-bring-treasure-trove-of-lifesaving-medtech-global-to-markets; and “Norway is driving major medical breakthroughs” — https://businessnorway.com/articles/four-medical-breakthroughs-from-norway.

Public contact: Stefan Kernstock, CEO; s.kernstock@sero.no.